P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Vs Belantamab Mafodotin for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Abstract
Authors
P. Moreau S.Z. Usmani N.W.C.J. van de Donk A.L. Garfall M. Delforge A. Oriol A. Nooka L. Rosiñol N. Bahlis P. Rodriguez Otero T.G. Martin J. Diels S. Van Sanden L. Pei E. Ammann K. Chastain A. Marshall M. Slavcev A. Londhe A. Krishnan